The study however had certain limitations, one of them being that the pooled outcomes of SGLT-2 inhibitors under the same intervention group caused an inability to assess the differences in HF outcomes between different drugs particularly given the dual inhibition of SGLT-2 and SGLT-1 by Sotagliflozin which could not be assessed. The gene discussed is SLC5A1; the disease is hydrops fetalis.